Pulmonary Drug Delivery describes various systems, devices, formulations, and methods of delivery of drugs to the lung for the treatment of diseases of the respiratory tract for systemic delivery via the lung. it offer advantages that Supply drugs into the bloodstream directly. Its allow for those molecules that currently can only be delivered by injection. Growing attention has been given to the potential of a pulmonary route as an non-invasive administration for systemic delivery of therapeutic agents (mainly peptides and proteins) due to the fact that the lungs provides an big surface area through which molecules can be absorbed and goes direct into the bloodstream. The conducting airways branch 12–23 times and their surface area measures approximately 0.8m.sq.In adults could provide a large absorptive surface area (up to 100 m2 ) but extremely thin (0.1 μm – 0.2 μm) absorptive mucosal membrane and good blood supply. However, recent advances show great promise, but pulmonary delivery of peptides and proteins is complicated by the complexity of the anatomic structure of the human respiratory system and the effect of disposition exerted by the respiration process.
The present presentation includes
> Route of administration
> Aerodynamic diameter
> Methods of inhalation delivery
A. Pressurized metered-dose inhalers (mdis or pmdis)
B. Dry powder inhalers (dpis)
>Approaches in pulmonary delivery
>Challenges in pulmonary delivery
Key words: Dry powder inhaler, handling, preference, asthma, COPD diabetes, vaccination and cancer.
Profile page link of the author : http://www.pharmainfo.net/harsh-bansal/biography
Profile page link of the guide: http://www.pharmainfo.net/atul-gupta/biography